Receive our newsletter – data, insights and analysis delivered to you
June 29, 2009

Zebinix Anti-Epileptic Shows Long-Term Success

Research conducted at Yale University School of Medicine has shown that Zebinix, a once-daily anti-epileptic drug, can help to decrease seizure frequency over the long term. Results from a one-year extension of an Eslicarbazepine Acetate Phase III study showed that an add-on treatment wit

By cms admin

Research conducted at Yale University School of Medicine has shown that Zebinix, a once-daily anti-epileptic drug, can help to decrease seizure frequency over the long term.

Results from a one-year extension of an Eslicarbazepine Acetate Phase III study showed that an add-on treatment with once-daily anti-epileptic Zebinix (eslicarbazepine acetate; ESL) showed a sustained decrease in seizure frequency over the long term.

Patients not on existing anti-epileptic drugs who were given Zebinix as an add-on treatment experienced a mean reduction in seizure frequency of more than 61%.

Yale University School of Medicine research scientist and president of The Epilepsy Therapy Project Joyce Cramer said that the data continue to demonstrate the efficacy and safety of Zebinix in the treatment of partial onset seizures.

“The availability of eslicarbazepine acetate adds an important new choice of therapy for patients who are in vital need of better seizure control,” Cramer said.

The data was pooled from over 1,000 patients enrolled in the three pivotal Phase III studies.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU